Expert Opinion on Drug Safety
Volume 22, 2023 - Issue 2
Original Research
Safety and tolerability of spesolimab in patients with ulcerative colitis
Marc Ferrantea Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, BelgiumCorrespondence[email protected]
https://orcid.org/0000-0003-1492-0716View further author information
https://orcid.org/0000-0003-1492-0716View further author information, Peter M Irvingb IBD Centre, Guy’s and St Thomas’ NHS Foundation Trust London, London, UKhttps://orcid.org/0000-0003-0972-8148View further author information
https://orcid.org/0000-0003-0972-8148View further author information, Christian P Selingerc Gastroenterology Department, The Leeds Teaching Hospitals NHS Trust, St James’s University Hospital, Leeds, UKhttps://orcid.org/0000-0003-2022-5859View further author information
https://orcid.org/0000-0003-2022-5859View further author information, Geert D’Haensd Inflammatory Bowel Disease Centre, Academic Medical Centre, Amsterdam, Netherlandshttps://orcid.org/0000-0003-2784-4046View further author information
https://orcid.org/0000-0003-2784-4046View further author information, , Ursula Seidlerf Medizinische Hochschule Hannover, Klinik für Gastroenterologie, Hepatologie und Endokrinologie, Hannover, Germanyhttps://orcid.org/0000-0002-9600-2769View further author information
https://orcid.org/0000-0002-9600-2769View further author information, , , , Silvio Daneseh Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, Milan, Italyhttps://orcid.org/0000-0001-7341-1351View further author information
https://orcid.org/0000-0001-7341-1351View further author information, & show all